Valuation: CEL-SCI Corporation

Market Cap 24.27M 21.74M 20M 18.12M 33.87M 2.3B 34.5M 238M 95.72M 1.21B 91.09M 89.16M 3.82B P/E 2026 *
-0.45x
P/E 2027 * -0.22x
Enterprise Value 18.72M 16.76M 15.42M 13.97M 26.12M 1.78B 26.61M 184M 73.82M 935M 70.25M 68.76M 2.95B EV / Sales 2026 *
-
EV / Sales 2027 * 3.17x
Free-Float
96.29%
Yield 2026 *
-
Yield 2027 * -
10-26 CEL-SCI Corporation Presents New Phase 3 Multikine Data and Positive New Pre-Surgical Tumor Response and Safety Analyses CI
09-15 CEL-SCI Corporation Presents Findings From Phase 3 Study Of Multikine At 6th World Congress On Otology, Rhinology And Laryngology CI
08-15 CEL-SCI Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
08-04 CEL-SCI Corporation Publishes Study Supporting Multikine Biomarker Strategy And Reports Survival Benefit In Oral Cancer CI
07-31 Certain Common Stock of CEL-SCI Corporation are subject to a Lock-Up Agreement Ending on 31-JUL-2026. CI
07-31 Certain Warrants of CEL-SCI Corporation are subject to a Lock-Up Agreement Ending on 31-JUL-2026. CI
07-31 Certain Stock Options of CEL-SCI Corporation are subject to a Lock-Up Agreement Ending on 31-JUL-2026. CI
07-30 CEL-SCI Corporation Announces Oncology Journal Accepts for Publication New Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients CI
07-13 CEL-SCI Corporation Launches FDA Registration-Enabling Phase 3 Confirmatory Study of Multikine for Newly Diagnosed Head and Neck Cancer CI
07-13 CEL-SCI to Launch Confirmatory Study of Multikine MT
06-24 Cel-Sci Corporation and Saudi Amarox Sign Agreement for Multikine Commercialization in Saudi Arabia CI
06-17 CEL-SCI Closes $2.5 Million Stock Offering MT
06-16 CEL-SCI Corporation and Amarox Enter Distribution and Commercialization Agreement for Multikine in Saudi Arabia CI
1 day-8.00%
1 week-15.85%
1 month-33.01%
3 months+18.97%
6 months-55.05%
Current year-73.76%
1 week 1.36
Extreme 1.36
1.83
1 month 1.36
Extreme 1.36
2.83
Current year 0.89
Extreme 0.89
6.75
1 year 0.89
Extreme 0.89
7.8
3 years 0.89
Extreme 0.89
96.91
5 years 0.89
Extreme 0.89
384.64
10 years 0.89
Extreme 0.89
1,227.42
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Director/Board Member 73 22/06/2015
Chairman 69 08/07/2024
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Chief Executive Officer

2,621 0.0149%
30/09/26 Free

Chief Financial Officer

2,082 0.0118%
30/09/26 Free

Chief Technology Officer

1,165 0.0066%
Change 5-day change 1-year change 3-year change Capi.($)
-8.00%-15.85%-80.54%-97.18% 24.27M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.49%+5.20%+34.77%+165.77% 39.44B
Weighted average by Cap. +0.18%+5.44%+47.98%+176.65%

Financials

2026 *2027 *
Net sales - 5.97M 5.35M 4.92M 4.46M 8.33M 567M 8.49M 58.67M 23.55M 298M 22.41M 21.94M 941M
Net income -25.08M -22.47M -20.66M -18.72M -35M -2.38B -35.65M -246M -98.92M -1.25B -94.14M -92.14M -3.95B -29.51M -26.43M -24.31M -22.03M -41.18M -2.8B -41.95M -290M -116M -1.47B -111M -108M -4.65B
Net Debt -5.55M -4.97M -4.58M -4.15M -7.75M -527M -7.89M -54.56M -21.9M -277M -20.84M -20.4M -875M -5.34M -4.78M -4.4M -3.99M -7.45M -507M -7.59M -52.45M -21.06M -267M -20.04M -19.61M -841M
Projected Income Statement - Annual - CEL-SCI Corporation
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
44
Date Price Change Volume
30/10/26 $1.380 -8.00% 189,970
29/10/26 $1.500 -6.25% 78,382
28/10/26 $1.600 +1.91% 99,402
27/10/26 $1.570 -1.26% 117,639
26/10/26 $1.590 -3.05% 106,854
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - CEL-SCI Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.380USD
Average target price
12.50USD
Spread / Average Target
+805.80%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - CEL-SCI Corporation